2023 World Conference on Lung Cancer (Posters)-P1.22. Patient Experiences of Biomarker Testing: Insights from a Global Patient Experience Survey

P1.22. Patient Experiences of Biomarker Testing: Insights from a Global Patient Experience Survey - PDF(Abstract)

Pdf Summary

In a global survey conducted by the Global Lung Cancer Coalition (GLCC), it was found that almost 70% of respondents had received a biomarker test for lung cancer. However, about 1 in 5 respondents were unsure if they had been tested. Of those who had been tested, only about half knew what biomarkers their cancer had, while 1/3 were waiting for test results. Nearly 1 in 5 patients who had been tested did not know their biomarker status. <br /><br />The survey also revealed that patients from Canada were the most knowledgeable about their biomarker status, while those from Israel had the lowest rates of understanding. This indicates that there may be gaps in patient information and communication about biomarker tests.<br /><br />The results of the survey highlight the importance of clear communication between healthcare professionals, service providers, and patient support groups in educating patients about biomarker testing. Patients have a right to informed self-determination, and it is crucial for them to understand the results and implications of these tests. <br /><br />Improving the clarity of communication about biomarker testing can help more patients access personalized treatment, support, and care. The findings from this survey can be used to inform efforts to enhance patient education and ensure that patients have the information they need to make informed decisions about their treatment options.

Asset Subtitle

Jackie Fenemore

Meta Tag

Speaker Jackie Fenemore

Topic Pathology & Biomarkers: Genetic Biomarkers

Keywords

global survey

Global Lung Cancer Coalition

biomarker test

lung cancer

respondents

knowledgeable

biomarker status

patient information

communication

patient education